ATE433988T1 - Phosphoramidatderivate - Google Patents

Phosphoramidatderivate

Info

Publication number
ATE433988T1
ATE433988T1 AT05701927T AT05701927T ATE433988T1 AT E433988 T1 ATE433988 T1 AT E433988T1 AT 05701927 T AT05701927 T AT 05701927T AT 05701927 T AT05701927 T AT 05701927T AT E433988 T1 ATE433988 T1 AT E433988T1
Authority
AT
Austria
Prior art keywords
phosphoramidate derivatives
ester
present
provides
phosphoramidate
Prior art date
Application number
AT05701927T
Other languages
English (en)
Inventor
Christopher Mcguigan
Antonella Carangio
Bruce Caterson
Clare Hughes
Clare Louise Curtis
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff filed Critical Univ Cardiff
Application granted granted Critical
Publication of ATE433988T1 publication Critical patent/ATE433988T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Luminescent Compositions (AREA)
AT05701927T 2004-01-19 2005-01-18 Phosphoramidatderivate ATE433988T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0401088.0A GB0401088D0 (en) 2004-01-19 2004-01-19 Phosphoramidate derivatives
PCT/GB2005/000161 WO2005070944A1 (en) 2004-01-19 2005-01-18 Phosphoramidate derivatives

Publications (1)

Publication Number Publication Date
ATE433988T1 true ATE433988T1 (de) 2009-07-15

Family

ID=31726385

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05701927T ATE433988T1 (de) 2004-01-19 2005-01-18 Phosphoramidatderivate

Country Status (9)

Country Link
US (1) US8119779B2 (de)
EP (1) EP1709056B1 (de)
JP (1) JP5137403B2 (de)
AT (1) ATE433988T1 (de)
DE (1) DE602005014936D1 (de)
DK (1) DK1709056T3 (de)
ES (1) ES2328495T3 (de)
GB (1) GB0401088D0 (de)
WO (1) WO2005070944A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
EP2471802A1 (de) 2010-12-27 2012-07-04 Bioiberica, S.A. Phosphoramidate aus Monosacchariden
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
GB201111779D0 (en) 2011-07-08 2011-08-24 Univ Cardiff Chemical compounds
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
AR089650A1 (es) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
EP2852604B1 (de) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclische phosphoramidat-prodrugs für hcv-infektion
MD20140134A2 (ro) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
EP2970357B1 (de) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Aminosäure-phosphoramidat-pronukleotide von 2'-cyano-, azido- und aminonukleosiden zur behandlung von hcv
EP2981542B1 (de) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluor-nukleoside zur behandlung von hcv
EP3004130B1 (de) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thionukleoside zur behandlung von hcv
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP3131914B1 (de) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituierte methyl- oder alkynylnukleoside zur behandlung von hcv
FI3265102T3 (fi) 2015-03-06 2025-10-31 Atea Pharmaceuticals Inc Beta-d-2'-deoksi-2'-alfa-fluori-2'-beta-c-substituoituja-2-modifioituja-n6-substituoituja puriininukleotideja hcv-hoitoa varten
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
WO2019118486A1 (en) * 2017-12-11 2019-06-20 Cerecor Inc. Monosaccharide phosphoramidate prodrugs
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
WO2026151964A1 (en) 2025-01-10 2026-07-16 Atea Pharmaceuticals, Inc. Compositions and use thereof in treating hepatitis e infections with beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059272A1 (en) * 1990-04-12 1991-10-13 Akira Hasegawa 4,6-0-hydroxyphosphoryl-glucosamine derivatives
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
ES2172303T3 (es) * 1998-01-23 2002-09-16 Newbiotics Inc Agentes terapeuticos obtenidos por catalisis enzimatica.
US6030957A (en) 1998-06-29 2000-02-29 Wayne Hughes Institute Aryl phosphate derivatives of d4T having anti-HIV activity
GB9821058D0 (en) 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
PT1150988E (pt) 1999-02-12 2003-10-31 Glaxo Group Ltd Esteres fosforamidato e mono-, di- e tri-fosfato de (1r,cis)-4- (6-amino-9h-purin-9-il)-2-ciclopenteno-1-metanol como agentes antivirais
CA2317305A1 (en) * 2000-08-29 2002-02-28 Tassos P. Anastassiades Method of enhancing chondrocyte cell growth and glycosaminoglycan production
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives

Also Published As

Publication number Publication date
US20070275910A1 (en) 2007-11-29
ES2328495T3 (es) 2009-11-13
GB0401088D0 (en) 2004-02-18
JP2007518734A (ja) 2007-07-12
EP1709056A1 (de) 2006-10-11
DK1709056T3 (da) 2009-08-10
EP1709056B1 (de) 2009-06-17
US8119779B2 (en) 2012-02-21
WO2005070944A1 (en) 2005-08-04
JP5137403B2 (ja) 2013-02-06
DE602005014936D1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
DK1709056T3 (da) Phosphoramidatderivater
HRP20090113T3 (hr) C-aril glukozid sglt2 inhibitori i postupak za njihovu proizvodnju
AR110313A2 (es) Derivados de tiazol-2-il-pirrolidina
TNSN08191A1 (en) Kinase inhibitors
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
HRP20120323T1 (en) Diarylhydantoin compounds
TW200728307A (en) Novel spirochromanone derivatives
TW200508228A (en) Biaryl heterocyclic compounds and methods of making and using the same
AU2006304874A8 (en) Pyrimidinones as casein kinase II (CK2) modulators
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2007117465A3 (en) Indazole compounds
ATE495176T1 (de) Spiroindolinon-derivate
WO2007084728A3 (en) 2-imino-benzimidazoles
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
GT200300087A (es) 2-(2,6-diclorofenil)-diarilimidazoles
TNSN07414A1 (fr) Formes cristallines anhydres de n-[1-(2-ethoxyethyl) -5- (n-ethyl-n-methylamino) -7-(4-methylpyridine -2- yl-amino) -1h-pyrazolo [4,3-d] pyrimidine -3- carbonyl]methanesulfonamide
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
WO2006047528A3 (en) Pyrazolobenzamides and derivatives as factor xa inhibitors
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
NO20084543L (no) Benzimidazolderivater
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
EA200801200A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛИЗОХИНОЛИНМОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ p38 КИНАЗЫ
TW200621160A (en) Anti-termite agent
WO2007023342A3 (en) Process of making geminal bisphosphonic acids and pharmaceutically acceptable salts and/or hydrates thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties